Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,444 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OPTIMAL Clear all
Completed Phase 2 Interventional Results available

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

NCT01132846
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Placebo, Nesiritide, Dopamine
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Decoding and Modulating Affective Brain States

NCT05437705
View directory record Official record
Conditions
Rumination, Major Depressive Disorder, Anxiety
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging

NCT01129635
View directory record Official record
Conditions
Heart Failure, Systolic, Left Bundle Branch Block
Interventions
Cardiac Resynchronization Therapy (CRT) implantation
Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Phase 4 Interventional

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

NCT06765668
View directory record Official record
Conditions
Parkinson Disease
Interventions
CREXONT ER
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aliso Viejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 30, 2026, 2:19 PM EDT
Withdrawn Phase 2 Interventional

Selective CD28 Blockade in Renal Transplant Recipients

NCT04903054
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplant Recipients
Interventions
Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 30, 2026, 2:19 PM EDT
Completed No phase listed Observational

Predicting Endometrial Receptivity for Optimal Reproductive Management

NCT04107129
View directory record Official record
Conditions
Infertility, Female, Endometriosis
Interventions
Endometrial Biopsy, Euploid embryo transfer, Blood sample
Procedure · Other · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

NCT01668719
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions
Bortezomib, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
417
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 30, 2026, 2:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)

NCT05499507
View directory record Official record
Conditions
Pregnancy Related, Hypertension, Obesity, Racism
Interventions
COH+
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older · Female only
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

NCT03446807
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Targeting Insomnia in School Aged Children With Autism Spectrum Disorder

NCT04545606
View directory record Official record
Conditions
Insomnia Chronic, Autism Spectrum Disorder
Interventions
In-Person CBT for insomnia in children with autism, Remote CBT for insomnia in children with autism, Remote sleep hygiene and related education (SHARE) for insomnia in children with autism
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
6 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 30, 2026, 2:19 PM EDT
Not listed Phase 1 Interventional

HIPEC After Initial CRS in Patients Who Have Received NACT

NCT03540017
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application

NCT05506085
View directory record Official record
Conditions
Laryngeal Dystonia, Adductor Spastic Dysphonia of Dystonia
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

Imetelstat Combinations in Relapsed AML

NCT07320235
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Imetelstat, Azacitidine, Venetoclax
Drug
Lead sponsor
Douglas Tremblay
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Withdrawn Phase 2 Interventional

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

NCT03150836
View directory record Official record
Conditions
Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Terence Friedlander, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 30, 2026, 2:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
View directory record Official record
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve System, furosemide infusion
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Irvine, California • Long Beach, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription

NCT03588910
View directory record Official record
Conditions
Surgery
Interventions
Acetaminophen, Ibuprofen 600 mg, Oxycodone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 30, 2026, 2:19 PM EDT
Not listed Not applicable Interventional

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

NCT02145286
View directory record Official record
Conditions
Metastatic Bone Lesion
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Paul W. Read, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Impact of Bed Provision and Sleep Education

NCT04536766
View directory record Official record
Conditions
Sleep Disturbance, Sleep Deprivation, Sleep, Insomnia
Interventions
Enhanced Sleep Health Education, Beds for Kids Standard Program
Behavioral
Lead sponsor
Saint Joseph's University, Philadelphia
Other
Eligibility
8 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Surgical Site Infection and Antibiotic Use Study

NCT04631185
View directory record Official record
Conditions
Surgical Site Infection, Breast Reconstruction, Antibiotic Use
Interventions
Single pre-operative dose of intravenous antibiotics with intraoperative redosing, One week of post-operative antibiotics
Drug
Lead sponsor
The Plastic Surgery Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study

NCT02042625
View directory record Official record
Conditions
Hypothermia
Interventions
Nasopharyngeal
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 30, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

NCT03220217
View directory record Official record
Conditions
Gastro-Enteropancreatic Neuroendocrine Tumor
Interventions
Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 30, 2026, 2:19 PM EDT